Composition for preventing or reducing nephrotoxicity and use thereof

Patent metadata

Field	Value
Publication number	US-10933033-B2
Application number	US-201916282203-A
Country	US
Kind code	B2
Filing date	Feb 21, 2019
Priority date	Feb 22, 2018
Publication date	Mar 2, 2021
Grant date	Mar 2, 2021

Abstract

A composition for preventing or reducing nephrotoxicity, and use thereof are provided, the composition including a Hypoxylon truncatum extract or an active component thereof.

First claim

What is claimed is:

1. A method of treating or reducing kidney cell damage in a subject or ex vivo, the method comprising contacting a composition with kidney cells,
wherein the composition comprises any stereoisomers of the group consisting of compounds represented by Formulae I, II, and III, or solvates, hydrates, mixtures, or pharmaceutically acceptable salts thereof:

wherein, in Formulae I, II, and III, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each independently H or (C 1 -C 6 )-alkyl.

2. The method of claim 1 , wherein the contacting comprises administering the composition to the subject.

3. The method of claim 1 , wherein the kidney cells are proximal tubule cells.

4. The method of claim 2 , further comprising administering a nephrotoxic compound to the subject.

5. The method of claim 4 , wherein the nephrotoxic compound is selected from the group consisting of a platinum-based anticancer agent, gentamicin, an iodinated contrast agent, foscarnet, mannitol, amphotericin B, acetoaminophen, and chloroform.

6. The method of claim 4 , wherein the administering of the composition is performed before, during, or after the administering of the nephrotoxic compound.

7. The method of claim 1 , wherein the kidney cell damage is apoptosis of kidney cells.

8. A method for treating or reducing nephrotoxicity in a subject, the method comprising contacting a composition with kidney cells,
wherein the composition comprises any stereoisomers of the group consisting of compounds represented by Formulae I, II, and III, or solvates, hydrates, mixtures, or pharmaceutically acceptable salts thereof:

wherein, in Formulae I, II, and III, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each independently H or (C 1 -C 6 )-alkyl.

9. The method of claim 8 , wherein R 1 and R 3 are each independently H or (C 1 -C 6 )-alkyl, and R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each H.

10. The method of claim 9 , wherein R 1 and R 3 are each independently H, methyl, or ethyl.

11. The method of claim 8 , wherein the compounds represented by Formulae I, II, and III are present in the composition in a weight ratio of 1.0:0.20 to 0.60:0.50 to 1.00.

12. The method of claim 8 , wherein the composition further comprises a pharmaceutically acceptable carrier or diluent.

13. The method of claim 8 , wherein the nephrotoxicity is caused by a nephrotoxic compound.

14. The method of claim 13 , wherein the nephrotoxic compound is selected from the group consisting of a platinum-based anticancer agent, gentamicin, an iodinated contrast agent, foscarnet, mannitol, amphotericin B, acetoaminophen, and chloroform.

15. The method of claim 14 , wherein the platinum-based anticancer agent is cis-diaminodichloroplatinum II (cisplatin), carboplatin, oxaliplatin, or nedaplatin.

16. The method of claim 8 , wherein the composition reduces apoptosis of kidney cells.

17. The method of claim 8 , wherein the nephrotoxicity is acute renal failure.

Assignees

• Korea Inst Sci & Tech

Inventors

• Ham Jungyeob
• Park Young Tae
• Kim Taejung
• Kim Young Seok
• Choi Pilju
• Kim Kyusun
• Choi Seonjun
• Song Bonggeun
• Kang Kisung
• Hwang Buyng Su
• Lee Dahae
• Song Jihoon

Classifications

• A61K31/05 Primary

  Phenols {(cannabinoids A61K31/658)} · CPC title

• A61K31/122 Primary

  having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin · CPC title

• A61K2236/33

  involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones · CPC title

• A61P13/12

  of the kidneys · CPC title

• A61K31/09

  having two or more such linkages · CPC title